HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $22

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises the price target from $20 to $22.